Antibodies Target Antigen Developed by Indication Status
Ipilimumab CTLA-4 Bristol-Myers Squibb Metastatic Melanoma FDA approval
Bevacizumab VEGF-A Genentech/Roche Metastatic colon cancer FDA approval
Panorex 17-1A EpCAM GlaxoSmithKline/Centocor Colorectal cancer German approval
Rituxan CD20 IDEC Pharm Non-Hodgkin’s Lymphoma FDA approval
Herceptin Her2/neu Genentech Metastatic Breast cancer FDA approval
MoAb730 Tumor antigen on DU145 cell line Talwar Research Foundation Castration-resistant prostate cancer cells DU145 and PC3 Preclinical development
MoAb7B2G10 Tumor antigen on PC3 cell line Talwar Research Foundation Castration-resistant prostate cancer cells DU145 and PC3 Preclinical development
MoAb3C8D4 Tumor antigen on PC3 cell line Talwar Research Foundation Castration-resistant prostate cancer cells DU145 and PC3 Preclinical development
PiPP β subunit of human chorionic gonadotropin (hCGβ) Talwar Research Foundation Advanced stage cancers ectopically expressing hCG Preclinical development
PiPP-curcumin conjugate β subunit of human chorionic gonadotropin (hCGβ) Talwar Research Foundation Kills MOLT-4 cells (human T-lymphoblastic leukemia cells) and U-937 cells (histolytic lymphoma cells) Preclinical development
MoAbCC4 Carcinoembryonic antigen (CEA) National laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing Colorectal cancer Preclinical development
Nivolumab PD-1 Bristol-Myers Squibb Renal cell cancer, melanoma, castration resistant prostate cancer, non–small cell lung cancer, colorectal cancer Undergone Phase-I trial
Lambrolizumab PD-1 Merck Solid cancers Undergone Phase-I trial
Pidilizumab PD-1 CureTech Ltd. Advanced hematologic Malignancies Undergone Phase-I trial
MoAb BMS-936559 PD-L1 Bristol-Myers Squibb Non-small-cell lung cancer, melanoma, renal cell carcinoma Undergone Phase-I trial
Vaccines
Sipuleucel-T Prostatic acid phosthatase Dendreon Castration-resistant prostate cancer FDA approval
Racotumomab NeuGcGM3 Recombio Advanced stage lung cancer Argentina and Cuba approval
Oncophage HSPPC-96 Antigenics.Inc. Kidney cancer Russian approval
PANVAC Carcinoembryonic antigen (CEA) National Institute of Health (NIH), USA Ovarian and breast cancers Undergone Phase-I trial
CEA-LTB Carcinoembryonic antigen (CEA) Talwar Research Foundation Advanced stage cancers ectopically expressing CEA Preclinical development
ProstVac-VF Prostate specific antigen National Institute of Health (NIH), USA Castration-resistant prostate cancer Undergone Phase-I trial
CDX-1307 β subunit of human chorionic gonadotropin (hCGβ) Celldex Advanced epithelial cancers expressing hCGβ Undergone Phase-I trial
hCGβ-LTB β subunit of human chorionic gonadotropin (hCGβ) Talwar Research Foundation Advanced stage cancers ectopically expressing hCGβ Ready for clinical trials
LHRH-D-Lys-R-N=CH-(CH2)3-CH=N-DT Luteinizing-Hormone-Releasing Hormone (LHRH) Talwar Research Foundation Carcinoma of prostate Undergone successfully Phase II trials in 3 centers in India and Austria
Table 2: Antibodies and vaccines against cancers and their status.